Nektar Therapeutics (NASDAQ: NKTR) reports $229.1M cash

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

Q: What cash balance did Nektar Therapeutics (NKTR) report as of January 31, 2026?

Q: How did Nektar Therapeutics present the $229.1 million cash figure in its 8-K?

Q: Is Nektar Therapeutics’ cash update in the 8-K considered filed or furnished?

Q: What section of the Exchange Act does Nektar reference regarding liability for this cash disclosure?

Q: What type of information does Nektar say the January 31, 2026 cash figure does not represent?

8-K Event Classification

What cash balance did Nektar Therapeutics (NKTR) report as of January 31, 2026?

How did Nektar Therapeutics present the $229.1 million cash figure in its 8-K?

Is Nektar Therapeutics’ cash update in the 8-K considered filed or furnished?

What section of the Exchange Act does Nektar reference regarding liability for this cash disclosure?

What type of information does Nektar say the January 31, 2026 cash figure does not represent?

Nektar Therapeutics reported having approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026 . This amount is an estimate based on information available at the time and does not represent full financial statements.

The company presented the $229.1 million cash and marketable securities balance as an estimate derived from information available on the announcement date. It emphasized this is not a comprehensive statement of operating results or complete financial position for January 31, 2026.

The cash update is expressly described as furnished , not filed. Nektar states the information under Item 7.01 is not deemed filed under Section 18 of the Exchange Act and is only incorporated into other filings if specifically referenced.

Nektar references Section 18 of the Securities Exchange Act of 1934 , stating the furnished information is not subject to that section’s liabilities. It also notes it will not be incorporated into Securities Act or Exchange Act filings unless expressly referenced.

Nektar explains the $229.1 million figure does not constitute a comprehensive statement of operating results or overall financial position as of January 31, 2026. It is limited to cash and investments in marketable securities based on currently available information.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Nektar Therapeutics provided a liquidity update, stating it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This figure is described as an estimate based solely on information available at the time of the announcement.

The company notes that this cash and investment balance is not a comprehensive statement of its operating results or full financial position for that date. The information was furnished under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other securities filings.

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Understanding 8-K Material Events →

02/10/2026 - 04:21 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 10, 2026

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)


Delaware	0-24006	94-3134940
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	NKTR	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.

Regulation FD.

On February 10, 2026, Nektar Therapeutics (the “Company”) announced it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This announcement reflects the Company’s estimates based solely upon information available to it as of the date of the announcement, and the amounts reported are not a comprehensive statement of its operating results or financial position as of January 31, 2026.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Nektar Therapeutics reported having approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This amount is an estimate based on information available at the time and does not represent full financial statements.

The company presented the $229.1 million cash and marketable securities balance as an estimate derived from information available on the announcement date. It emphasized this is not a comprehensive statement of operating results or complete financial position for January 31, 2026.

The cash update is expressly described as furnished, not filed. Nektar states the information under Item 7.01 is not deemed filed under Section 18 of the Exchange Act and is only incorporated into other filings if specifically referenced.

Nektar references Section 18 of the Securities Exchange Act of 1934, stating the furnished information is not subject to that section’s liabilities. It also notes it will not be incorporated into Securities Act or Exchange Act filings unless expressly referenced.

Nektar explains the $229.1 million figure does not constitute a comprehensive statement of operating results or overall financial position as of January 31, 2026. It is limited to cash and investments in marketable securities based on currently available information.

NEKTAR THERAPEUTICS

Date: February 10, 2026

/s/ Elizabeth Zhang

Elizabeth Zhang

Vice President, Legal

3 documents